PFE Jan 2025 55.000 call
| Previous close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0100 |
| Ask | 0.0500 |
| Strike | 55.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0200 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.91k |
- Yahoo Finance Video
Pfizer: Starboard Value pushes for investigation of board
Pharmaceutical giant Pfizer (PFE) is butting heads with activist investor Starboard Value, as Starboard demands an investigation into the actions of Pfizer's board. Yahoo Finance Senior Health Reporter Anjalee Khemlani details the situation, tracing the timeline of Starboard Value's involvement with Pfizer and exploring the factors that have led to the current tensions. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Angel Smith
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
Business WireU.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK, October 11, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors.
